CN1212145C - Extract of rhizome of Chinese paris and its use - Google Patents
Extract of rhizome of Chinese paris and its use Download PDFInfo
- Publication number
- CN1212145C CN1212145C CN 03117809 CN03117809A CN1212145C CN 1212145 C CN1212145 C CN 1212145C CN 03117809 CN03117809 CN 03117809 CN 03117809 A CN03117809 A CN 03117809A CN 1212145 C CN1212145 C CN 1212145C
- Authority
- CN
- China
- Prior art keywords
- extract
- rhizoma paridis
- paris
- medicine
- herpes simplex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses an extract of paris root, and an application thereof. The extract of paris root can be prepared by the following method: whole grass meal of paris plants is used as raw materials, 30 to 100% etanol accounting for 3 to 30 shares by weight of the raw materials is added, and reflux extraction is carried out for three times at 0 to 90 DEG C; extracting solution is merged, etanol solution is decompressed and recovered, and is degreased by activated carbon to obtain wet extractum, the specific gravity of the wet extractum is 1.05, and the wet extractum is the required extract of paris root. Antivirotic pharmacodynamic tests in vitro show that the extract has herpesvirus resistant function, high pharmacological action, wide adaptability and good medicinal prospect.
Description
Technical field
The present invention relates to a kind of Chinese herbal and crude drugs preparations, more particularly, the present invention relates to a kind of extract of Rhizoma Paridis, simultaneously, the invention still further relates to the purposes of described Rhizoma Paridis extract in pharmaceutical field.
Background technology
Find that from 19 end of the centurys tobacco mosaic virus (TMV), people recognize that virus is a kind of microorganism littler than antibacterial, find again that subsequently the animal and the mankind all can be subjected to similar filterability viral infection.Clinical discovery, increasing disease is relevant with virus, and the statistics confirmation almost has 3/4 infectious disease to be caused by virus.Viral and clinical not only relation is very close, and relation is quite complicated.A kind of virus can cause multiple disease, and a kind of disease can be caused by multiple virus.In a sense, human evolution's history, the history of just human and various virus trials of strength.
(herpes simplex virus HSV) belongs to herpes virus section, the about 180nm of viral diameter to simple herpes virus.Visible particle is made up of concentric multilamellar under the Electronic Speculum.Internal layer is a core, in double-stranded DNA and albumen are arranged.Its skin is the protein housing of 20 bodies, and these 20 bodies are made up of 162 column shell microgranules.Outermost layer is a peplos, is made up of fat and sugar albumen.The antigenic specificity of glycoprotein decision HSV, tunicary virion is easier to be adsorbed on the cell, thereby has more infectivity.
HSV has two kinds of antigenic types, i.e. HSV-I and HSV-II type, and the biological characteristics of amphitypy virus and epidemiological significance are inequality.The I type is the main pathogen of herpes labialis and big child and adult HSVE; The II type then mainly causes reproductive tract bleb disease and neonate whole body disseminated infections, also can cause encephalitis or meningitis, and relevant with the morbidity of cervical cancer.HSVE case more than 95% is by due to the I type.The people who infects herpes simplex is the unique reservoir host of this virus.Mainly by the directly contact closely between the crowd, the HSV-I type still can pass through the air droplet transmission in the route of transmission, and the main trafficability characteristic life of HSV-II type is propagated, and can pass through direct contact infection neonate when childbirth.The herpesvirus serious harm mankind's is healthy.
But, in the prior art, still there is not the specific medicament of anti-herpesvirus, especially lack taking convenience, toxic and side effects is little, and the significant Chinese medicine preparation of therapeutic effect.Effective treatment to the herpesvirus disease is still a technical barrier that urgency is to be solved.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, a kind of Rhizoma Paridis extract is provided.It with the natural plants is raw material, and is with low cost, and the anti-herpesvirus effect is remarkable, and toxic and side effects is low, is indicating well prospect in medicine.The present invention also provides the purposes of described Rhizoma Paridis extract.
Purpose of the present invention is achieved by following technical proposals.
Except as otherwise noted, the percent that is adopted among the present invention is percetage by weight.
The invention provides a kind of Rhizoma Paridis extract, this Rhizoma Paridis extract can be prepared by following method: with Paris Linnaeus(Paris L.) (Paris) plant herb powder is raw material, be incorporated as 30%～100% ethanol of 3 parts～30 parts of raw material weights, reflux, extract, is three times under 0 ℃～90 ℃ temperature; Merge extractive liquid,, decompression recycling ethanol liquid and through the active carbon defat obtains wet extractum, and its proportion is 1.05, is needed Rhizoma Paridis extract.
Beneficial effect:
1. Chinese preventive medicine science institute Ins of Virology experimentizes extract of the present invention to herpes simplex virus (HSV-I), details are as follows for the experiment situation.
Experiment material: 1. verify medicine: extract powder of the present invention, 2. African green monkey kidney cell (VERO), herpes simplex virus (HSV-I) and Eagle`s keep liquid provides by this institute.
Experimental technique:
A. herpes simplex virus toxicity test (cytopathy political reform CPE)
1. virus is kept 10 times of serial dilutions of liquid promptly with Eagle`s: 10
-1～10
-7
2. will dilute good virus inoculation to cultivating in VERO cell 96 well culture plates in blocks, every concentration 4 holes, 37 ℃ of 5%CO are put in 0.1 milliliter in every hole
2Cultivated 24～48 hours, the observation of cell pathological changes is established the normal cell contrast simultaneously.Observation of cell pathological changes under the inverted microscope, the record result.Experimental result: herpes simplex virus (HSV-I) TCID
50Be 10
-5
The toxicity test of B. described extract pair cell
1. extract is kept liquid with Eagle`s respectively and be diluted to different concentration, be inoculated into VERO cell (about 20,000 of every porocyte) 96 well culture plates of growing in blocks respectively, every concentration 4 holes, every hole 0.1ml puts 37 ℃ of 5%CO
2Cultivated 7 days, microscopically observation of cell pathological changes, with every porocyte 25% be+, 25%～50% destroys and to be ++, 50%～75% destroys and is +++, 75%～100% destroys and is ++ ++.Write down the poisoning situation of every porocyte, calculate TD
0The maximal non-toxic concentration of medicine pair cell.
2. experimental result: as shown in table 1.
Table 1. extract of the present invention is to VERO cytotoxicity experiment result
| Tested number | Experimental technique | Toxicity T D0 (μ g/ml) to the VERO cell |
| 1 | The reflection cytotoxicity | 75μg/ml |
| 2 | The reflection cytotoxicity | 37.5μg/ml |
C. the extracorporeal antivirus effect test of pesticide effectiveness (cytopathy political reform CPE)
The VERO cell inoculation is cultured to monolayer for 37 ℃ to 96 well culture plates (about 20,000 of every porocyte), discards growth-promoting media.2. herpes simplex virus (HSV-1) is diluted to 10
-5, absorption is 2 hours in every hole 0.1ml inoculation VERO cell, discards viral liquid.3. the maximal non-toxic concentration that adds the medicine pair cell of two batches of experiments.2 times are diluted to different concentration, every concentration inoculation infected cell 4 holes, every hole 0.1ml.Establish virus control, normal cell contrast simultaneously.Put 37 ℃ of 5%CO
2Cultivated observation of cell pathological changes 7 days 24～48 hours.Record CPE.4. experimental result: as shown in table 2.
Table 2. extract of the present invention is to the inhibitory action of herpes simplex virus (HSV-I) pathological changes
| The experiment number | Experimental technique | The experiment batch | HSV-MIC(μg/ml) |
| 1 | The observation of cell pathological changes | 1 | ＜0.58 |
| 2 | ＜0.58 | ||
| 2 | The observation of cell pathological changes | 1 | ＜0.29 |
| 2 | ＜0.29 |
Above-mentioned result of the test shows that extract of the present invention has antivirus action to herpes simplex virus (HSV-I), and minimum effective drug concentration is 0.29～0.58 μ g/ml.
2. the Rhizoma Paridis extract of the present invention's preparation detects through Fudan University's study of pharmacy, and details are as follows for detection case.
Test item: the external efficacy of medicine observing of Rhizoma Paridis extract
Materials and methods: 1. cell in vitro model Vero, 2. Strain HSV-II333 strain, the 3. toxicity of mtt assay test sample pair cell, 4. observation of cell pathological changes (CPE) is determined the inhibitory action of medicine to HSV-II.
Antivirus test: 1. the Vero cell was cultivated in 96 porocyte culture plates after 2 days, added the medicine of variable concentrations, continued to cultivate 3 days, used the mtt assay detection of drugs to Vero.2. the Vero cell is cultivated after 2 days in 96 porocyte culture plates, uses 10TCTD
50Amount HSV-II infection cell at the medicinal liquid that adds maximal non-toxic concentration, was cultivated observation of cell pathological changes (CPE) situation 3 days.
Testing result: as shown in table 3.
Table 3. medicine of the present invention is to the toxicity and anti-herpesvirus (HSV-II) the effect situation of Vero cell
| Sample number into spectrum | Maximal non-toxic concentration TCD 0 (μg/ml) | To the effective inhibition concentration of HSV-II (μ g/ml) | The TI value |
| 1 | 1.2 | 0.6 | 2 |
| 2 | 2.4 | 0.6 | 4 |
Above-mentioned result of the test clearly illustrates that extract of the present invention can suppress herpesvirus HSV-II effectively when concentration is 0.6 μ g/ml.
Above-mentioned result of the test shows that extract of the present invention has the function of anti-herpesvirus, and pharmacological action is strong, and indication is wide, is indicating well prospect in medicine.Raw material sources are abundant, inexpensive, and preparation technology is simple, for the distinctive plant resources in Yunnan has been opened up new application.
The specific embodiment
By specific embodiment given below, can further be well understood to the present invention.But they are not limitation of the invention.
Embodiment 1
With Rhizoma Paridis herb powder 1000 grams, add 30% ethanol 5000 grams, reflux, extract, is three times under 80 ℃ of temperature; Merge extractive liquid,, decompression recycling ethanol liquid and through the active carbon defat obtains wet extractum, and its proportion is 1.05, is required extract.
Embodiment 2
Remove and get Rhizoma Paridis herb powder 1000 grams, add 60% ethanol 5000 grams, outside refluxing under 60 ℃ of temperature, other process is identical with embodiment 1.
Embodiment 3
Remove and get Rhizoma Paridis herb powder 1000 grams, add 90% ethanol 5000 grams, outside refluxing under 0 ℃ of temperature, other process is identical with embodiment 1.
Claims (3)
1. the application of Rhizoma Paridis extract in the medicine of the disease that preparation treatment or prevention herpes simplex virus cause, described Rhizoma Paridis extract is to be prepared by following method: be raw material with the paris plant, be incorporated as 30%～100% ethanol of 3 parts～30 parts of raw material weights, reflux, extract, is three times under 0 ℃～90 ℃ temperature; Merge extractive liquid,, decompression recycling ethanol liquid and through the active carbon defat obtains wet extractum, and its proportion is 1.05, is needed Rhizoma Paridis extract.
2. the application of the described Rhizoma Paridis extract of claim 1 in the medicine of the disease that preparation treatment or prevention herpes simplex virus type 1 cause.
3. the application of the described Rhizoma Paridis extract of claim 1 in the medicine of the disease that preparation treatment or prevention herpes simplex II type virus cause.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117809 CN1212145C (en) | 2003-04-30 | 2003-04-30 | Extract of rhizome of Chinese paris and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117809 CN1212145C (en) | 2003-04-30 | 2003-04-30 | Extract of rhizome of Chinese paris and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1481857A CN1481857A (en) | 2004-03-17 |
| CN1212145C true CN1212145C (en) | 2005-07-27 |
Family
ID=34152702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03117809 Expired - Fee Related CN1212145C (en) | 2003-04-30 | 2003-04-30 | Extract of rhizome of Chinese paris and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1212145C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102430033A (en) * | 2010-09-29 | 2012-05-02 | 苏州瑞蓝博中药技术开发有限公司 | Preparation method for schefflera arboricola hayata total saponins |
| CN110229066B (en) * | 2019-06-18 | 2021-11-12 | 云南省农业科学院生物技术与种质资源研究所 | Penicillium ester-III compound and preparation method, preparation and application thereof |
-
2003
- 2003-04-30 CN CN 03117809 patent/CN1212145C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1481857A (en) | 2004-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114053343B (en) | Traditional Chinese medicine composition, preparation method and application | |
| WO2005067955A1 (en) | Antimicrobial activity from medicinal mushrooms | |
| CN111297969A (en) | Application of Chaihingzhi preparation in preparing anti-coronavirus medicine and its preparation method | |
| CN102824417B (en) | New method for treating helicobacter pylori related diseases | |
| CN1872105A (en) | Application of holly and extractive in preparing medication for anti virus | |
| CN1330330C (en) | Antivirus medicinal composition, preparation method and use | |
| CN1212145C (en) | Extract of rhizome of Chinese paris and its use | |
| CN108403858B (en) | Callicarpa nudiflora extract composition for treating hand-foot-and-mouth disease and application thereof | |
| CN111632116A (en) | Preparation method of traditional Chinese medicine preparation for resisting viral cold | |
| CN115105502B (en) | Application of compound containing stephania plant alkaloid in preparation of cat infectious peritonitis medicine | |
| CN108186866B (en) | Application of golden scallop oral liquid in antivirus | |
| CN103356812B (en) | A kind of Radix Wikstroemae granule | |
| JP5709762B2 (en) | Anti-Dengue Thermal Activity of Cissam Pero Spareira Extract | |
| CN1250240C (en) | Isatis root extract, and preparing method and use thereof | |
| CN113318141A (en) | Application of agrimony extract | |
| CN1318077C (en) | Antivirus Chinese medicine compound preparation and its preparation method | |
| CN1259043C (en) | Application of salvia acid in pharmacy | |
| CN113975312B (en) | Antiviral drug composition, method for inhibiting in vitro virus activity and application | |
| CN103356813B (en) | Indian stringbush root capsule | |
| CN113181229B (en) | Application of cabbage type rape-isatis tinctoria G monomer addition system in inhibiting novel coronavirus SARS-CoV-2 | |
| CN103356717B (en) | Rhizoma Dryopteris Crassirhizomatis extract and its use in preparation of viral disease controlling medicines | |
| CN102697800A (en) | Chickweed polysaccharide composition and applications thereof in preparation of antiviral medicine | |
| CN111228362B (en) | Application of Shuangyang pharyngitis particles in treating diseases caused by coronavirus infection | |
| KR20060042299A (en) | Antiviral composition against rhinovirus | |
| CN113230288A (en) | Application of thesium or thesium extract as novel coronavirus therapeutic drug or antiviral preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN BAIYAO GROUP CO.,LTD. Free format text: FORMER OWNER: NATURAL MEDICINE INSTITUTE OF YUNNAN BAIYAO GROUP Effective date: 20100506 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650118 NO.222, SECOND RING WEST ROAD, KUNMING CITY, YUNNAN PROVINCE TO: 650118 NATIONAL HIGH-TECH INDUSTRY DEVELOPMENT AREA, KUNMING CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100506 Address after: 650118 Kunming national hi tech Industrial Development Zone Patentee after: Yunnan Baiyao Group Corp., Ltd. Address before: 650118 No. 222 West Second Ring Road, Yunnan, Kunming Patentee before: Natural Medicine Inst., Yunan Baiyao Group |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050727 Termination date: 20210430 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |